Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial
Thrombocytopenic patients have an increased risk of bleeding when undergoing invasive procedures. In a multicentre, phase II, blinded, randomised, controlled feasibility trial, critically ill patients with platelet count 100 × 109/L or less were randomised 1:1 to intravenous desmopressin (0.3 µg/kg)...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley Open Access
2024
|
| _version_ | 1811139701790212096 |
|---|---|
| author | Desborough, MJR Laing, E Kounali, D Mora, A Hodge, R Martin, S Thomas, H Hudson, C Parsons, J Shah, A Hutton, P Parke, T Wise, MP Morgan, M McKechnie, S Stanworth, SJ |
| author_facet | Desborough, MJR Laing, E Kounali, D Mora, A Hodge, R Martin, S Thomas, H Hudson, C Parsons, J Shah, A Hutton, P Parke, T Wise, MP Morgan, M McKechnie, S Stanworth, SJ |
| author_sort | Desborough, MJR |
| collection | OXFORD |
| description | Thrombocytopenic patients have an increased risk of bleeding when undergoing invasive procedures. In a multicentre, phase II, blinded, randomised, controlled feasibility trial, critically ill patients with platelet count 100 × 109/L or less were randomised 1:1 to intravenous desmopressin (0.3 µg/kg) or placebo before an invasive procedure. Forty‐three participants (18.8% of those eligible) were recruited, with 41 eligible for analysis. Post‐procedure bleeding occurred in one of 22 (4.5%) in the placebo arm and zero of 19 in the desmopressin arm. Despite liberal inclusion criteria, there were significant feasibility challenges recruiting patients in the critical care setting prior to invasive procedures. |
| first_indexed | 2024-09-25T04:10:17Z |
| format | Journal article |
| id | oxford-uuid:454b48e9-30ea-45a3-8217-e57c93bfdb57 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:10:17Z |
| publishDate | 2024 |
| publisher | Wiley Open Access |
| record_format | dspace |
| spelling | oxford-uuid:454b48e9-30ea-45a3-8217-e57c93bfdb572024-06-16T20:05:09ZDesmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:454b48e9-30ea-45a3-8217-e57c93bfdb57EnglishJisc Publications RouterWiley Open Access2024Desborough, MJRLaing, EKounali, DMora, AHodge, RMartin, SThomas, HHudson, CParsons, JShah, AHutton, PParke, TWise, MPMorgan, MMcKechnie, SStanworth, SJThrombocytopenic patients have an increased risk of bleeding when undergoing invasive procedures. In a multicentre, phase II, blinded, randomised, controlled feasibility trial, critically ill patients with platelet count 100 × 109/L or less were randomised 1:1 to intravenous desmopressin (0.3 µg/kg) or placebo before an invasive procedure. Forty‐three participants (18.8% of those eligible) were recruited, with 41 eligible for analysis. Post‐procedure bleeding occurred in one of 22 (4.5%) in the placebo arm and zero of 19 in the desmopressin arm. Despite liberal inclusion criteria, there were significant feasibility challenges recruiting patients in the critical care setting prior to invasive procedures. |
| spellingShingle | Desborough, MJR Laing, E Kounali, D Mora, A Hodge, R Martin, S Thomas, H Hudson, C Parsons, J Shah, A Hutton, P Parke, T Wise, MP Morgan, M McKechnie, S Stanworth, SJ Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial |
| title | Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial |
| title_full | Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial |
| title_fullStr | Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial |
| title_full_unstemmed | Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial |
| title_short | Desmopressin for prevention of bleeding for thrombocytopenic, critically ill patients undergoing invasive procedures: A randomised, double‐blind, placebo‐controlled feasibility trial |
| title_sort | desmopressin for prevention of bleeding for thrombocytopenic critically ill patients undergoing invasive procedures a randomised double blind placebo controlled feasibility trial |
| work_keys_str_mv | AT desboroughmjr desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT lainge desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT kounalid desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT moraa desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT hodger desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT martins desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT thomash desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT hudsonc desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT parsonsj desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT shaha desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT huttonp desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT parket desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT wisemp desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT morganm desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT mckechnies desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial AT stanworthsj desmopressinforpreventionofbleedingforthrombocytopeniccriticallyillpatientsundergoinginvasiveproceduresarandomiseddoubleblindplacebocontrolledfeasibilitytrial |